Source comparison
MK-677 Per Day Daily Dose: Clinical vs Research Comparison
10mg Muscle protein synthesis preservation, sleep quality studies, minimal effective dose trials +40–50% Mild appetite increase, transient water retention (1–2kg), minimal glucose impact Ideal starting dose for long-term protocols; lowest side effect burden wh
This comparison does not assign a generated winner or score.
- 10mg
- Muscle protein synthesis preservation, sleep quality studies, minimal effective dose trials
- +40–50%
- Mild appetite increase, transient water retention (1–2kg), minimal glucose impact
- Ideal starting dose for long-term protocols; lowest side effect burden while maintaining anabolic signaling
- 15mg
- Body recomposition studies, elderly sarcopenia research, moderate GH amplification
- +60–70%
- Moderate appetite stimulation, 2–3kg fluid retention, fasting glucose +5–10 mg/dL
- Balanced dose for sustained use; sufficient IGF-1 elevation without significant metabolic disruption
- 20mg
- Maximal muscle preservation during caloric deficit, bone density studies
- +75–85%
- Increased appetite, 3kg water retention, mild lethargy, fasting glucose +8–12 mg/dL
- Near-ceiling GH response; side effects become dose-limiting for many subjects
- 25mg
- Maximal IGF-1 elevation research, GH deficiency studies, clinical trial standard
- +85–90%
- Significant appetite surge, 3–4kg fluid retention, moderate insulin resistance markers, daytime fatigue
- Receptor saturation achieved; higher doses yield no additional hormonal benefit but increase adverse event frequency
- 50mg+
- Not used in legitimate research protocols
- +90–95% (no meaningful increase vs 25mg)
- Severe water retention, marked fasting hyperglycemia, persistent lethargy, increased risk of insulin resistance
- Exceeds receptor saturation threshold. Adverse effects outweigh any marginal benefit